Clover Biopharmaceuticals AUS Pty

Clinical trials sponsored by Clover Biopharmaceuticals AUS Pty, explained in plain language.

Now part of Clover Biopharmaceuticals, Ltd. 2197 HKEX

A subsidiary of Clover Biopharmaceuticals, a vaccine developer.

Not investment advice. Company information is shown for context only. Clinical trials frequently fail.

Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.

Not yet finished but already full! 1

Triple-Threat vaccine aims to shield seniors from three respiratory viruses

Vaccine Ongoing

This study tests two new vaccines (SCB-1022 and SCB-1033) designed to protect against RSV, human metapneumovirus, and parainfluenza virus. About 612 healthy adults aged 60-85 will receive either a vaccine or a placebo. The main goal is to check safety and how well the vaccines tr…

Phase 1/2 • Sponsor: Clover Biopharmaceuticals AUS Pty • Aim: Vaccine

Last updated Jun 27, 2026 12:35 UTC

Clover Biopharmaceuticals AUS Pty

Triple-Threat vaccine aims to shield seniors from three respiratory viruses